Browse > Home / Drug News / Valcyte Approved for Cytomegalovirus in Children

Valcyte Approved for Cytomegalovirus in Children

August 31, 2009

Valcyte Approved because of Cytomegalovirus in Children

A leading cause of infection in transplant patients

CMV disease is a frequent bane among people who have had an voice carry. Such patients may have being infected with CMV under the jurisdiction their surgeries, or be receiving organs that are infected, Roche said in a news set free. Children are at increased risk of CMV infection and serious complications when their immune systems are suppressed to prevent rejection of donor organs.

CMV infects about 80 percent of the U.S. population, the body said, and in most cases lies quiescent in the material part. But when the immune system is weakened, CMV complications could concern the lungs, kidneys, nervous system, liver and gastrointestinal tract — potentially leading to serious illness or dissolution.

As part of the approval, the FDA sanctioned a new oral liquid form of the drug to allow toward easier use in children, Roche said.

The put drugs into has not been evaluated in transport patients under 4 months of period of life, the company said.

More information

The FDA has more about this drug’s history.

Written by Samanta · Filed Under Drug News